Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Restoring vision in vivo in a rat model of acquired blindness using BENAQ
EF 2017-18
Résumé
Age-related macular degeneration (AMD) is a progressive disease causing irreversible blindness. Affecting over 8 million people in the United States, AMD is the leading cause of blindness in developed countries. AMD ultimately targets photoreceptors, the primary light detecting cells of the retina, and causes them to deteriorate. Despite other retinal cells remaining intact, the eye is no longer able to respond to light and thus cannot send visual information to the brain. Current treatment options for AMD are invasive, irreversible, or ineffective.Recently a series of drugs, called photoswitches, have shown promising therapeutic potential due to their ability to restore light sensitivity in retinas where photoreceptor loss has occurred. In this project the photoswitch BENAQ will be used due to its long lasting and non-toxic qualities. Remarkably, BENAQ works by entering retinal ganglion cells, which are ordinarily unresponsive to light, and induces light dependent responses. However, this has so far only been demonstrated with genetic models, despite AMD being an acquired disease associated with age. Additionally, it is not well understood how the visual cortex responds when BENAQ is applied to the retina. Therefore, this project aims to examine cortical response to BENAQ application in a model of acquired retinal degeneration. To accomplish this, a rat model of AMD will be established using sodium iodate, a drug which induces photoreceptor loss. BENAQ will then be injected in the eye, and retinal and cortical responses will be recorded and quantified via electrodes placed on the cornea and in the visual cortex. Overall, this study will help determine if BENAQ is an effective treatment for restoring vision in an acquired retinal disease.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
386380
Name
GERRIE Heather J
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Restoring vision in vivo in a rat model of acquired blindness using BENAQ
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Age-Related Macular Degeneration; Electrophysiology; Electroretinogram; Macular Degeneration; Photoswitches; Retina; Retinal Disease; Retinal Dysfunction; Visual Neuroscience
Abstract
Age-related macular degeneration (AMD) is a progressive disease causing irreversible blindness. Affecting over 8 million people in the United States, AMD is the leading cause of blindness in developed countries. AMD ultimately targets photoreceptors, the primary light detecting cells of the retina, and causes them to deteriorate. Despite other retinal cells remaining intact, the eye is no longer able to respond to light and thus cannot send visual information to the brain. Current treatment options for AMD are invasive, irreversible, or ineffective.Recently a series of drugs, called photoswitches, have shown promising therapeutic potential due to their ability to restore light sensitivity in retinas where photoreceptor loss has occurred. In this project the photoswitch BENAQ will be used due to its long lasting and non-toxic qualities. Remarkably, BENAQ works by entering retinal ganglion cells, which are ordinarily unresponsive to light, and induces light dependent responses. However, this has so far only been demonstrated with genetic models, despite AMD being an acquired disease associated with age. Additionally, it is not well understood how the visual cortex responds when BENAQ is applied to the retina. Therefore, this project aims to examine cortical response to BENAQ application in a model of acquired retinal degeneration. To accomplish this, a rat model of AMD will be established using sodium iodate, a drug which induces photoreceptor loss. BENAQ will then be injected in the eye, and retinal and cortical responses will be recorded and quantified via electrodes placed on the cornea and in the visual cortex. Overall, this study will help determine if BENAQ is an effective treatment for restoring vision in an acquired retinal disease.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
GERRIE, Heather J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~